Empowering eye care practitioners with wearable, cloud-connected diagnostic tools designed for the earliest detection of retinal dysfunction, before structural damage and vision loss occur.
Retinal diseases silently damage vision years before they damage structure, visible in standard imaging tests. For most patients, night vision loss is the earliest alarm of retinal dysfunction.
Vision loss from retinal diseases is growing rapidly due to the aging population. Currently, 57 million Americans have undiagnosed functional retinal impairment, progressing without the eye clinic's ability to measure it and intervene.
Traditional diagnostic modalities often catch retinal diseases only after structural tissue damages are deeply established. Tracking dark adaptation recovery time via a wearable, patient-friendly device turns a vague complaint of night vision loss into a quantifiable biomarker.
If you plan to attend AAOptom in Anaheim, CA this year, we invite you to visit EVOQ Technologies during September 30th to October 3rd at Booth 566 as we exhibit at the meeting for the first time.
Read More >Patent covers a mobile-device-based system that delivers visual stimulation and wirelessly records ocular electrophysiological responses.
Read More >Dr. Hein-Peters takes responsibility for expanding EVOQ Technologies' market presence and driving revenue growth through fundraising, strategic partnerships and product launches.
Read More >